Homocysteine‐Lowering Treatment and the Risk of Fracture: Secondary Analysis of a Randomized Controlled Trial and an Updated Meta‐Analysis

High plasma homocysteine is a risk factor for osteoporotic fractures. Several studies have assessed the possible preventive effect of homocysteine‐lowering B‐vitamin treatment on the risk of fracture with inconclusive results. In the current study, we include new results from the Aspirin Folate Poly...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia Lopez, Maria, Baron, John A, Omsland, Tone K, Søgaard, Anne Johanne, Meyer, Haakon E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139704/
https://www.ncbi.nlm.nih.gov/pubmed/30283911
http://dx.doi.org/10.1002/jbm4.10045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139704/
https://www.ncbi.nlm.nih.gov/pubmed/30283911
http://dx.doi.org/10.1002/jbm4.10045

Ejemplares similares